On October 13, 2022 Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, reported the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which targets human papillomavirus (HPV)-driven cancers (Press release, Nutcracker Therapeutics, OCT 13, 2022, View Source [SID1234622006]). The company will present this data at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), being held in Boston, MA, from November 8-12, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation will showcase data that demonstrates that NTX-0250, a multimodal, mRNA-based therapeutic, is capable of inducing the complete regression of large murine tumors. The details about the presentation and session information are as follows:
Title: NTX-0250, a multimodal mRNA-based immunotherapy, eradicates large established tumors in a stringent mouse model of HPV16-driven cancer.
Abstract Number: 1084
Presentation Session: Immune-stimulants and immune modulators
Presentation Date and Time: Friday, Nov. 11, 2022, 11:55–1:25 p.m. and Poster Reception (7–8:30 p.m.)
Lead Author: Ole A.W. Haabeth
Poster presentations will be accessible in person and virtually. All accepted abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Nov. 7 at 8 a.m. EST. For more information about the 37th SITC (Free SITC Whitepaper) annual meeting, please visit View Source